Safety and pharmacokinetic profiles of MGS0274 besylate (TS‐134), a novel metabotropic glutamate 2/3 receptor agonist prodrug, in healthy subjects-Reference-Cited by-同舟云学术

Safety and pharmacokinetic profiles of MGS0274 besylate (TS‐134), a novel metabotropic glutamate 2/3 receptor agonist prodrug, in healthy subjects

Published:2020-06-10 Issue:11 Volume:86 Page:2286-2301
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:Br J Clin Pharmacol

Author:

Watanabe Mai¹^ORCID,Marcy Brian¹,Kinoshita Kohnosuke²^ORCID,Fukasawa Misako²,Hikichi Hirohiko²,Chaki Shigeyuki²,Okuyama Shigeru²,Gevorkyan Hakop³,Yoshida Shigeru²

Affiliation:

1. Taisho Pharmaceutical R&D Inc. NJ USA

2. Taisho Pharmaceutical Co., Ltd. Tokyo Japan

3. California Clinical Trials Medical Group CA USA

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bcp.14331

Reference33 articles.

1. Glutamatergic Dysfunction and Glutamatergic Compounds for Major Psychiatric Disorders: Evidence From Clinical Neuroimaging Studies

2. Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders

3. Neuroplasticity of Neocortical Circuits in Schizophrenia

4. Cortical parvalbumin interneurons and cognitive dysfunction in schizophrenia

5. The NMDA Antagonist Model for Schizophrenia: Promise and Pitfalls

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Novel Inhibitory Site Revealed by XAP044 Mode of Action on the Metabotropic Glutamate 7 Receptor Venus Flytrap Domain;Journal of Medicinal Chemistry;2024-05-01

2. Prodrugs as empowering tools in drug discovery and development: recent strategic applications of drug delivery solutions to mitigate challenges associated with lead compounds and drug candidates;Chemical Society Reviews;2024

3. Preclinical Metabolism and Disposition of TP0473292, a Novel Oral Prodrug of the Potent Metabotropic Glutamate 2/3 Receptor Antagonist TP0178894 for the Treatment of Depression;Drug Metabolism and Disposition;2023-02-08

4. Clinical investigations of compounds targeting metabotropic glutamate receptors;Pharmacology Biochemistry and Behavior;2022-09

5. The mGlu7 receptor in schizophrenia - An update and future perspectives;Pharmacology Biochemistry and Behavior;2022-07